MedTrace Logo

Effect of GLP-1 on Postprandial Lipid Metabolism

NCT01760772 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-01-04

No results posted yet for this study

Summary

Individuals with obesity have an increased risk for heart disease and diabetes. There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes. The investigators want to determine if targeting this hormone will also help people with high cholesterol and triglycerides. In this study, the investigators are looking at the role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.

Conditions

Interventions

DRUG

Exendin-9

Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min

DRUG

GLP-1

Constant infusion of GLP-1 at 0.3 pmol/kg/min

OTHER

saline

Constant infusion

Sponsors & Collaborators

  • David Dalessio

    lead OTHER

Principal Investigators

  • Michelle R Adams, PhD · University of Cincinnati

  • David D'Alessio, MD · University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01760772 on ClinicalTrials.gov